Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.

Tyrosine kinase inhibitor (TKI) therapy has revolutionised chronic myeloid leukaemia (CML) management, it is however associated with significant side effects and economic burden. Recent studies have demonstrated that treatment free remission is possible in certain patients. The aim of this study was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ulster Med J
Hauptverfasser: McMullan, RR, McConville, C, McMullin, MF
Format: Artigo
Sprache:Inglês
Veröffentlicht: The Ulster Medical Society 2019
Schlagworte:
Clinical Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500416/
https://ncbi.nlm.nih.gov/pubmed/31061559
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge